alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol and Basal Ganglia Diseases

alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol has been researched along with Basal Ganglia Diseases in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Borison, R; Gewirtz, GR; Gorman, JM; Gribkoff, G; Macaluso, J; Taylor, DP; Volavka, J	1

Trials

1 trial(s) available for alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol and Basal Ganglia Diseases

Article	Year
BMY 14802, a sigma receptor ligand for the treatment of schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 1994, Volume: 10, Issue:1 Topics: Adult; Anti-Anxiety Agents; Basal Ganglia Diseases; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Pyrimidines; Receptors, sigma; Schizophrenia; Schizophrenic Psychology; Single-Blind Method	1994

Article

Year

BMY 14802, a sigma receptor ligand for the treatment of schizophrenia.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 1994, Volume: 10, Issue:1

Topics: Adult; Anti-Anxiety Agents; Basal Ganglia Diseases; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Pyrimidines; Receptors, sigma; Schizophrenia; Schizophrenic Psychology; Single-Blind Method

1994